ONCC PRACTICE TESTS (OCN - CARE
CONTINUUM) WITH COMPLETE
SOLUTIONS
Which mof mthe mfollowing mis man madvantage mof man mimplanted mvascular maccess
mdevice mover ma mtunneled mcentral mvenous mcatheter?
mDecreased mrisk mof minfection
mShort-term muse
mLow mcost mof minsertion
mUnlimited mability mto maccess m- mcorrect manswers m-Decreased mrisk mof minfection
Answer: mImplanted mports mhave ma mlower mrisk mof minfection mthan mtunneled
mcentral mvenous mcatheters. m
, Reference: mCamp-Sorrell, mD., m& mMatey, mL. m(Eds.). m(2017). mAccess mdevice
mstandards mof mpractice mfor moncology mnursing. mPittsburgh, mPA: mOncology
mNursing mSociety, mp. m67.
The mnurse mteaches ma mpatient mthat mthe mpurpose mof ma mliving mwill mis mto:
mestablish mthe mpatient's mdesires mfor mcare mprior mto ma mlife-threatening millness.
mmake mfinal mdecisions mregarding mtreatment muntil mdisease mprogression.
macknowledge mthe mrisks mand mlimitations mof mrecommended mtherapies.
mappoint ma msurrogate mto mmake mmedical mdecisions. m- mcorrect manswers m-
establish mthe mpatient's mdesires mfor mcare mprior mto ma mlife-threatening millness.
Answer: mLiving mwills mare mdesigned mto mdetermine mthe mcare mthat ma mpatient mis
magreeable mto mreceive mor mnot mreceive min mthe mevent mof ma mterminal millness. m
Reference: mEggert, mJ. m(Ed.). m(2017). mCancer mbasics m(2nd med.). mPittsburgh,
mPA: mOncology mNursing mSociety, mp. m655(t).
Within mwhich mtimeframe mwill mchemotherapy-induced malopecia mnormally mbegin
mafter mreceiving ma mfirst mtreatment?
m
m2 mweeks
m24 mhours
m1 mmonth
m3 mmonths m- mcorrect manswers m-2 mweeks
Answer: mHair mloss mfrom mchemotherapy musually mbegins mtwo mweeks mafter
mbeginning mtreatment. m
Reference: mEggert, mJ. m(Ed.). m(2017). mCancer mbasics m(2nd med.). mPittsburgh,
mPA: mOncology mNursing mSociety, mp. m360.
A mpatient mwith mbreast mcancer mwho mreceived mcyclophospamide mfive myears mago
mreports ma mnew monset mof mbruising mand mfatigue. mThe mnurse msuspects:
ma msecondary mleukemia.
mliver mfailure.
mleukoencephalopathy.
mcardiomyopathy. m- mcorrect manswers m-a msecondary mleukemia.
Answer: mThe mrisk mof msecondary mleukemia mincreases mwith mthe muse mof
malkylating magents. m
CONTINUUM) WITH COMPLETE
SOLUTIONS
Which mof mthe mfollowing mis man madvantage mof man mimplanted mvascular maccess
mdevice mover ma mtunneled mcentral mvenous mcatheter?
mDecreased mrisk mof minfection
mShort-term muse
mLow mcost mof minsertion
mUnlimited mability mto maccess m- mcorrect manswers m-Decreased mrisk mof minfection
Answer: mImplanted mports mhave ma mlower mrisk mof minfection mthan mtunneled
mcentral mvenous mcatheters. m
, Reference: mCamp-Sorrell, mD., m& mMatey, mL. m(Eds.). m(2017). mAccess mdevice
mstandards mof mpractice mfor moncology mnursing. mPittsburgh, mPA: mOncology
mNursing mSociety, mp. m67.
The mnurse mteaches ma mpatient mthat mthe mpurpose mof ma mliving mwill mis mto:
mestablish mthe mpatient's mdesires mfor mcare mprior mto ma mlife-threatening millness.
mmake mfinal mdecisions mregarding mtreatment muntil mdisease mprogression.
macknowledge mthe mrisks mand mlimitations mof mrecommended mtherapies.
mappoint ma msurrogate mto mmake mmedical mdecisions. m- mcorrect manswers m-
establish mthe mpatient's mdesires mfor mcare mprior mto ma mlife-threatening millness.
Answer: mLiving mwills mare mdesigned mto mdetermine mthe mcare mthat ma mpatient mis
magreeable mto mreceive mor mnot mreceive min mthe mevent mof ma mterminal millness. m
Reference: mEggert, mJ. m(Ed.). m(2017). mCancer mbasics m(2nd med.). mPittsburgh,
mPA: mOncology mNursing mSociety, mp. m655(t).
Within mwhich mtimeframe mwill mchemotherapy-induced malopecia mnormally mbegin
mafter mreceiving ma mfirst mtreatment?
m
m2 mweeks
m24 mhours
m1 mmonth
m3 mmonths m- mcorrect manswers m-2 mweeks
Answer: mHair mloss mfrom mchemotherapy musually mbegins mtwo mweeks mafter
mbeginning mtreatment. m
Reference: mEggert, mJ. m(Ed.). m(2017). mCancer mbasics m(2nd med.). mPittsburgh,
mPA: mOncology mNursing mSociety, mp. m360.
A mpatient mwith mbreast mcancer mwho mreceived mcyclophospamide mfive myears mago
mreports ma mnew monset mof mbruising mand mfatigue. mThe mnurse msuspects:
ma msecondary mleukemia.
mliver mfailure.
mleukoencephalopathy.
mcardiomyopathy. m- mcorrect manswers m-a msecondary mleukemia.
Answer: mThe mrisk mof msecondary mleukemia mincreases mwith mthe muse mof
malkylating magents. m
